Pharmaceutical News

RSS

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

FDA accepts GPC Biotech's Satraplatin NDA

GPC Biotech AG has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed.

17 Apr 2007

Cytochroma and Genzyme settle lawsuit

Cytochroma Inc. announced that the lawsuit filed in August 2006 by Genzyme Corporation in the United States District Court, Western District of Wisconsin has been settled by the parties.

17 Apr 2007

Biomira selects PX-866 as clinical development candidate

Biomira Inc. has announced that it has selected PX-866 as its next clinical development candidate.

17 Apr 2007

Abbott and signs contract with Premier for diagnostic tests

Abbott has announced that it has signed a new group purchasing agreement with Premier, Inc., a leading healthcare alliance, for a broad line of the company's diagnostic products.

17 Apr 2007

AARP to track Senate vote on Medicare Rx bargaining bill

Today, AARP will be sending the following letter from CEO Bill Novelli to every member of the U.S. Senate alerting them that the association will be recording the upcoming Senate vote on a bill to allow Medicare to negotiate for lower prescription drug prices.

17 Apr 2007

Bristol-Myers Squibb announces new results of Baraclude (entecavir) resistance monitoring program

Bristol-Myers Squibb Company has announced new results of the Baraclude (entecavir) resistance monitoring program, which found a continued low incidence of resistance in studies of nucleoside-naive chronic hepatitis B patients through four years of treatment.

16 Apr 2007

Ranbaxy receives U.S. approval to market Loratadine Antihistamine tablets

Ohm Laboratories, a wholly owned subsidiary of Ranbaxy Laboratories Limited, has announced that Ranbaxy has received approval from the U. S. Food and Drug Administration to manufacture and commercialize its Loratadine Orally Disintegrating Tablets, 10mg. The antihistamine previously made the switch from the prescription to the OTC market.

15 Apr 2007

Use of computer-assisted drug design in drug discovery

Metabasis Therapeutics has announced that on March 27, 2007 at the American Chemical Society 233rd National Meeting and Exposition in Chicago, Dr. M. Rami Reddy presented, "Use of Computer-Assisted Drug Design in Drug Discovery: Limitations and Advantages of Available Computational Methods."

15 Apr 2007

Lupin Pharmaceuticals receives FDA approval for Suprax

Lupin Pharmaceuticals has announced that the U.S. Food and Drug Administration (US FDA) has approved the company's application for Suprax (Cefixime for oral suspension 200mg/5ml).

15 Apr 2007

Coley Pharmaceutical licenses VaxImmune to Merck

Coley Pharmaceutical Group has announced that Merck & Co has licensed Coley's VaxImmune vaccine adjuvant for incorporation into vaccines being developed by Merck for certain infectious diseases and Alzheimer's disease.

15 Apr 2007

BioMed Realty Trust embarks on $145 million expansion at Eastview

BioMed Realty Trust Breaks Ground on $145 Million Lab and Office Complex at The Landmark at Eastview

15 Apr 2007

Anika Therapeutics receives European stamp of approval for cosmetic dermatology product

Anika Therapeutics has announced that it has received CE Mark certification for the commercial sale of its cosmetic dermatology product, ELEVESS, in the European Union.

15 Apr 2007

Avista Capital acquires BioReliance from Invitrogen

Avista Capital Partners has announced it has completed its acquisition of BioReliance Corporation, a business unit of Invitrogen Corporation for approximately $210 million.

15 Apr 2007

Mylan announces FDA approval for Glipizide and Metformin Hydrochloride tablets

Mylan Laboratories has announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Glipizide and Metformin Hydrochloride Tablets in 2.5 mg/250 mg, 2.5 mg/500 mg and 5 mg/500 mg strengths.

14 Apr 2007

FDA approves GlaxoSmithKline's antibacterial Altabax

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved its antibacterial Altabax for the topical treatment of impetigo due to susceptible strains of Staphylococcus aureus or Streptococcus pyogenes, the two most common types of bacteria in this kind of infection.

14 Apr 2007